Headache

Bruising is reported in the BTN as well as in the placebo group in up to 40% of patients. Possible risk factors include co-medication with antico

The incidence of headaches in the evaluated clinical trials varies in the BTN as well as in the placebo group from 0%-30% (Table 7.3). Interestingly, headache is not only reported after injection of BTN in the glabella but also after treatment of the crow's feet area. Headaches are usually mild and last only for a few hours (Carruthers et al. 2002; Vartanian et al. 2005). Since, according to Alam et al., up to 1% of the patients develop a severe headache lasting 2-4 weeks, patients should

Table 7.1. Incidence of injection pain as documented in clinical trials

Author Year no. of patients

Drug and dose

Area of injection

% of injection pain in verum or different verum groups

% of injection pain in placebo group

Carruthers et al. 2003 n=59

Botox 16, 32, 48 U

Frontal

Not reported

Not applicable

Rzany et al. 2006 n=22l, l46 verum

Dysport, 3x10 U 5x10 U, placebo

Glabella and frontal

0.7

0

Carruthers et al. 2005 n=80

Botox 10, 20, 30, 40 U

Glabella and frontal

Not reported

Not applicable

Carruthers et al. 2002 n=264

Botox 20 U, placebo

Glabella

Not reported

Not reported

Carruthers et al. 2005 n=80

Botox 20, 40, 60, 80 U

Glabella

Not reported

Not applicable

Ascher et al. 2004 n=ll9

Dysport 25, 50, 75 U, placebo

Glabella

Not reported

Not reported

Lowe et al. 2005 n=l62

Botox 18, 12, 6, 3 U, placebo

Crow's feet

Not reported

Not reported

Baumann et al. 2003 n=20

Myobloc 500 U, placebo

Crow's feet

Not reported

Not reported

Table 7.2. Incidence of hematoma/injection site bruising

Author

Year no. of patients

Drug and dose

Area of injection

% of hematoma in verum or different verum groups

% of hematoma in placebo group

Carruthers et al. 2003 n=59

Botox 16, 32, 48 U

Frontal

10%, 5.3%, 15%

Not applicable

Rzany et al. 2006 n=221

Dysport, 3x10 U 5x10 U, placebo

Glabella and frontal

Not reported

Not reported

Carruthers et al. 2005a n=80

Botox 10, 20, 30,40 U

Glabella and frontal

Not reported

Not applicable

Carruthers et al. 2002 n=264

Botox 20 U, placebo

Glabella

Not reported

Not reported

Carruthers et al. 2005b n=80

Botox 20, 40, 60, 80 U

Glabella

5%, 0%, 0%, 0%

Not applicable

Ascher et al. 2004 n=119

Dysport 25, 50, 75 U, placebo

Glabella

0%, 3%, 0%

5.8%

Lowe et al. 2005 n=162

Botox 18, 12, 6, 3 U, placebo

3.0%

12.5%

Baumann et al. 2003 n=20

Myobloc 500 U, placebo

Crow's feet

25%

40%

Table 7.3. Incidence of headache

Author Year

No. of patients

Drug and dose

Area of injection

% of headache in verum or different verum groups

% of headache in placebo group

Carruthers et al. 2003 n=59

Botox 16, 32, 48 U

Frontal

20%, 15.8%, 30%

Not applicable

Rzany et al. 2006 n=221

Dysport, 3x10 U 5x10 U, placebo

Glabella and frontal

2.7

2.7

Carruthers et al. 2005 n=80

Botox 10, 20, 30, 40 U

Glabella and frontal

20%, 15%, 5%, 5%

Not applicable

Carruthers et al. 2002 n=264

Botox 20 U, placebo

Glabella

15.3%

15%

Carruthers et al. 2005 n=80

Botox 20, 40, 60, 80 U

Glabella

0%, 15%, 0%, 0%

Not applicable

Ascher et al. 2004 n=119

Dysport 25, 50, 75 U placebo

, Glabella

3%, 3%, 0%

0%

Lowe et al. 2005 n=162

Botox 18, 12, 6, 3 U, placebo

Crow's feet

6.1%, 3.2%, 6.1%, 12.1%

3.1%

Baumann et al. 2003 n=20

Myobloc 500 U, placebo

Crow's feet

25%

20%

be informed about the possibility of idiosyncratic severe headaches (Alam et al. 2002). On the other hand, the results of some studies point to a decrease in headache occurrence after repeated BNT treatment. However, these results were not significant (Carruthers et al. 2004).

Stop Headache Drug Free

Stop Headache Drug Free

If you are suffering from headaches, you can make the pain stop just by following some basic but little known principles. Take 15 minutes browsing through this guide and you'll find dozens of tips to gain control in the battle against headache pain.

Get My Free Audio Book


Post a comment